Arcturus Therapeutics
ARCT
23 hedge funds and large institutions have $17.7M invested in Arcturus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
159% more call options, than puts
Call options by funds: $381K | Put options by funds: $147K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
78% more capital invested
Capital invested by funds: $9.98M → $17.7M (+$7.75M)
21% more funds holding
Funds holding: 19 → 23 (+4)
0.73% more ownership
Funds ownership: 13.58% → 14.31% (+0.73%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
Top Sellers
ARCT Hedge Fund Activity: Q2 2019 in Review
23 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2019, worth a combined $17.7M — up 78% from $9.98M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ARCT positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Highline Capital Management, adding an estimated $1.25M. The largest seller was DAFNA Capital Management, cutting an estimated $329K.
- 23 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2019, up from 19 in Q1 2019.
- Funds reported $17.7M of Arcturus Therapeutics stock for Q2 2019, up 78% quarter-over-quarter.
- 8 funds opened new Arcturus Therapeutics positions in Q2 2019 and 4 closed out, a net change of +4 holders.
- The largest Arcturus Therapeutics buyer in Q2 2019 was Highline Capital Management, an estimated $1.25M added.
- The largest Arcturus Therapeutics seller in Q2 2019 was DAFNA Capital Management, an estimated $329K sold.
Based on aggregated 13F filings for Q2 2019.